You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 11, 2025

Suppliers and packagers for OMEPRAZOLE AND SODIUM BICARBONATE


✉ Email this page to a colleague

« Back to Dashboard


OMEPRAZOLE AND SODIUM BICARBONATE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant Tradename Generic Name Dosage NDA NDA/ANDA Supplier Package Code Package Marketing Start
Ajanta Pharma Ltd OMEPRAZOLE AND SODIUM BICARBONATE omeprazole; sodium bicarbonate CAPSULE;ORAL 204228 ANDA Ajanta Pharma USA Inc. 27241-031-03 30 CAPSULE in 1 BOTTLE (27241-031-03) 2016-07-15
Ajanta Pharma Ltd OMEPRAZOLE AND SODIUM BICARBONATE omeprazole; sodium bicarbonate CAPSULE;ORAL 204228 ANDA Ajanta Pharma USA Inc. 27241-032-03 30 CAPSULE in 1 BOTTLE (27241-032-03) 2016-07-15
Ajanta Pharma Ltd OMEPRAZOLE AND SODIUM BICARBONATE omeprazole; sodium bicarbonate CAPSULE;ORAL 204228 ANDA Direct_rx 72189-568-30 30 CAPSULE in 1 BOTTLE (72189-568-30) 2024-08-12
Ajanta Pharma Ltd OMEPRAZOLE AND SODIUM BICARBONATE omeprazole; sodium bicarbonate CAPSULE;ORAL 204228 ANDA PHOENIX RX LLC 85509-1031-1 15 CAPSULE in 1 BOTTLE (85509-1031-1) 2016-07-15
Ajanta Pharma Ltd OMEPRAZOLE AND SODIUM BICARBONATE omeprazole; sodium bicarbonate CAPSULE;ORAL 204228 ANDA PHOENIX RX LLC 85509-1031-3 30 CAPSULE in 1 BOTTLE (85509-1031-3) 2016-07-15
Ajanta Pharma Ltd OMEPRAZOLE AND SODIUM BICARBONATE omeprazole; sodium bicarbonate CAPSULE;ORAL 204228 ANDA PHOENIX RX LLC 85509-1031-6 60 CAPSULE in 1 BOTTLE (85509-1031-6) 2016-07-15
>Applicant >Tradename >Generic Name >Dosage >NDA >NDA/ANDA >Supplier >Package Code >Package >Marketing Start

Suppliers for the Pharmaceutical Drugs: Omeprazole and Sodium Bicarbonate

Last updated: July 30, 2025


Introduction

The pharmaceutical markets for omeprazole and sodium bicarbonate are characterized by a complex network of global suppliers, manufacturers, and distributors. Both drugs serve critical roles: omeprazole as a proton pump inhibitor (PPI) primarily used to treat gastroesophageal reflux disease (GERD), peptic ulcers, and Zollinger-Ellison syndrome; sodium bicarbonate as an antacid and bicarbonate source for metabolic acidosis management. Ensuring a reliable supply chain is vital for healthcare providers, pharmaceutical companies, and patients.


Omeprazole Suppliers

Major Pharmaceutical Manufacturers

Omeprazole was first developed by AstraZeneca and introduced under the brand name Prilosec. Today, it is widely produced by multiple generic manufacturers due to patent expirations. Key suppliers include:

  • AstraZeneca: Original innovator, still a significant player supplying branded formulations and active pharmaceutical ingredients (APIs) globally.
  • Teva Pharmaceutical Industries: One of the world’s largest generic manufacturers, producing OMEn products in multiple strengths.
  • Sandoz (Novartis): A leading generic supplier with extensive production capacity for omeprazole formulations.
  • Mylan (now part of Viatris): Provides both branded and generic omeprazole products globally.
  • Dr. Reddy’s Laboratories: An Indian pharmaceutical major with a broad portfolio, including omeprazole APIs and finished formulations.
  • Sun Pharmaceutical Industries: One of India's largest pharma firms, exporting omeprazole products worldwide.
  • Lupin Limited: An Indian-based manufacturer with a significant market share, especially in Asia and Africa.

API Suppliers

The raw material for omeprazole is complex to manufacture, involving multiple synthesis steps. Leading API suppliers include:

  • Hikal Ltd. (India)
  • Jiangsu Hengrui Medicine Co. Ltd. (China)
  • Kopper Medical Supplies (India)
  • Hoffmann-La Roche (Switzerland) (for some components in early manufacturing processes)

The supply of APIs is subject to regulatory approval and quality standards, which influences which suppliers are eligible for manufacturing.

Regional Supply Dynamics

  • India and China: Dominant in API manufacturing, providing cost-effective APIs to global generics companies.
  • Europe and North America: Focused mainly on finished formulations and brand-specific products, with some API sourcing from Asian suppliers.

Sodium Bicarbonate Suppliers

Bulk Chemical Suppliers

Sodium bicarbonate, or baking soda, is a widely produced inorganic compound. Suppliers range from large chemical conglomerates to specialty chemical producers:

  • ETA Ascon Group (India): A top producer of bicarbonates and other inorganic compounds.
  • Tata Chemicals (India): Major manufacturer with extensive global supply.
  • Solvay (Belgium): One of the world's largest producers of inorganic specialty chemicals, including baking soda.
  • Occidental Petroleum Corporation (USA): Supplies bicarbonate as part of their chemical product portfolio.
  • FMC Corporation: Provides industrial-grade sodium bicarbonate for pharmaceutical and food uses.

Pharmaceutical-Grade Producers

Pharmaceutical-grade sodium bicarbonate must meet stringent purity requirements. Notable suppliers include:

  • BASF (Germany): Offers high-purity formulations suitable for medicinal use.
  • Searle Chemicals (USA): Specialized in pharmaceutical excipients and intermediates.
  • GFS Chemicals (USA): Produces medical-grade bicarbonate solutions and powders.

Regional Supply Dynamics

  • Asia-Pacific: Leading in bulk chemical production due to lower manufacturing costs, with widespread distribution networks.
  • Europe and North America: Usage primarily in pharmaceutical and food industries, with established regulatory standards driving supplier selection.

Supply Chain Considerations

Regulatory Compliance

Suppliers must meet Good Manufacturing Practices (GMP) standards set by authorities such as the FDA (USA), EMA (Europe), and other national agencies. API suppliers require rigorous validation and documentation to ensure safety, efficacy, and quality.

Patent and Market Access

  • Omeprazole’s patent expiration in many regions has facilitated a surge in generic suppliers, expanding global availability.
  • Sodium bicarbonate, being a common inorganic compound, faces fewer patent restrictions, leading to increased competition among suppliers.

Supply Chain Risks

  • Raw material shortages and geopolitical factors have historically disrupted supplies, especially in APIs sourced from China and India.
  • Regulatory variances can delay approvals and certifications, impacting distribution timelines.

Emerging Trends and Future Outlook

  • The increasing focus on biosimilar and generic drug production is expected to expand supplier options for omeprazole.
  • Sustainable manufacturing practices are gaining importance, with suppliers investing in greener processes.
  • The growth of contract manufacturing organizations (CMOs) suggests that many pharmaceutical companies will rely more heavily on third-party suppliers for APIs and formulations.

Key Takeaways

  • The global supply of omeprazole is highly diversified, with major contributions from India, China, and established multinational entities like AstraZeneca and Teva.
  • API sourcing remains centered in Asia, which drives cost-efficiency but underscores supply chain vulnerabilities.
  • Sodium bicarbonate benefits from widespread industrial production, with key supply nodes in India, Belgium, and the US delivering pharmaceutical-grade material.
  • Regulatory compliance and quality assurance are critical when assessing suppliers, influencing procurement decisions.
  • The ongoing demand for generic and biosimilar drugs will further expand supplier networks, prompting closer monitoring of supply chain resilience.

FAQs

1. Who are the leading global suppliers of omeprazole APIs?
Major API suppliers include Jiangsu Hengrui Medicine (China), Hikal Ltd. (India), and Hoffmann-La Roche (Switzerland), supplying high-quality APIs compliant with international standards.

2. Are there regional differences in the quality of sodium bicarbonate suppliers?
Yes. While inorganic chemical producers in Asia and Europe supply bulk chemicals, pharmaceutical-grade sodium bicarbonate from companies like BASF and Searle Chemicals adhere to strict GMP standards.

3. How has patent expiration affected omeprazole supplier dynamics?
Patent expirations have facilitated the entry of numerous generic manufacturers, increasing supply options and reducing costs but also introducing variability in quality and regulatory compliance.

4. What risks are associated with API supply chains for omeprazole?
Dependence on Asia, especially China and India, presents risks of geopolitical disruptions, regulatory delays, and raw material shortages, emphasizing the need for diversified sourcing.

5. Will the demand for sodium bicarbonate impact its supply stability?
Given its widespread industrial and medical use, supply remains stable. However, increased demand for pharmaceutical-grade material demands strict quality controls and supply chain oversight.


References

[1] AstraZeneca Official Website. Omeprazole Product Information.
[2] Teva Pharmaceutical Industries. Product Portfolio Details.
[3] Sandoz Global Operations. API Manufacturing Reports.
[4] Sun Pharmaceutical Industries. Corporate Reports.
[5] BASF. Chemical Product Data Sheets.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.